Natural chalcones as dual inhibitors of HDACs and NF-κB

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 797-805

  Orlikova, B ^a   Schnekenburger, M ^a   Zloh, M ^b   Golais, F ^c   Diederich, M ^a   Tasdemir, D ^b,d  

^a Kirchberg Hospital   (Luxembourg)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c Physics and Informatics   (Slovakia)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Cancer; Chalcone; Dual inhibition; HDAC; Inflammation; Nf B

Indexed keywords

2 HYDROXYCHALCONE; 2' HYDROXYCHALCONE; 2,3 DIMETHOXY 2' HYDROXYCHALCONE; 3,4 DIMETHOXYCHALCONE; 4 HYDROXYCHALCONE; 4 METHOXYCHALCONE; 4' HYDROXYCHALCONE; 4' METHOXYCHALCONE; 4,4' DIMETHOXYCHALCONE; BUTEIN; CALMELANONE; CHALCONE; CHALCONE DERIVATIVE; ERIODICTYOCHALCONE; FLAVOKAWAIN A; FLAVOKAWAIN C; GYMNOGRAMMENE; HISTONE DEACETYLASE; HOMOBUTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOLIQUIRITIGENIN; MAREIN; PHLORETIN; PHLORIZIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; MOLECULAR DOCKING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CHALCONES; COMPUTER SIMULATION; GENE EXPRESSION REGULATION; GENES, REPORTER; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LUCIFERASES, RENILLA; MODELS, MOLECULAR; NF-KAPPA B; PROTEIN BINDING; REPRESSOR PROTEINS;

EID: 84865339754     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1870     Document Type: Article

References (43)

1. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
2. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
3. ten Holte P, Van Emelen K, Janicot M, Fong PC, de Bono JS and Arts J: HDAC inhibition in cancer therapy: an increasingly intriguing tale of chemistry, biology and clinical benefit. In: Cancer. Topics in Medicinal Chemistry. Bradbury RH (ed). Springer Verlag, Berlin, pp293-332, 2007.
4. Folmer F, Orlikova B, Schneckenburger M, Dicato M and Diederich M: Naturally occurring regulators of histone acetylation/ deacetylation. Curr Nutr Food Sci 6: 78-99, 2010.
5. Seidel C, Schnekenburger M, Dicato M and Diederich M: Histone deacetylase modulators provided by Mother Nature. Genes Nutr: Feb. 12, 2012 (Epub ahead of print).
6. Gibbons RJ: Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 14 (Suppl 1): R85-R92, 2005.
7. Lombardi PM, Cole KE, Dowling DP and Christianson DW: Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr Opin Struct Biol 21: 735-743, 2011.
8. Vannini A, Volpari C, Filocamo G, et al: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 101: 15064-15069, 2004.
9. Gupta SC, Sundaram C, Reuter S and Aggarwal BB: Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799: 775-787, 2010.
10. Vallabhapurapu S and Karin M: Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27: 693-733, 2009.
11. Batra S, Sahu RP, Kandala PK and Srivastava SK: Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells. Mol Cancer Ther 9: 1596-1608, 2010.
12. Jung ID, Lee JS, Jeong YI, et al: Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int J Immunopathol Pharmacol 22: 501-515, 2009.
13. Roth SY, Denu JM and Allis CD: Histone acetyltransferases. Annu Rev Biochem 70: 81-120, 2001.
14. Kiernan R, Bres V, Ng RW, et al: Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem 278: 2758-2766, 2003.
15. Hu J and Colburn NH: Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding. Mol Cancer Res 3: 100-109, 2005.
16. Lehmann A, Denkert C, Budczies J, et al: High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 9: 395, 2009.
17. Florean C, Schnekenburger M, Grandjenette C, Dicato M and Diederich M: Epigenomics of leukemia: from mechanisms to therapeutic applications. Epigenomics 3: 581-609, 2011.
18. Schnekenburger M and Diederich M: Epigenetics offer new horizons for colorectal cancer prevention. Curr Colorectal Cancer Rep 8: 66-81, 2012.
19. Papeleu P, Wullaert A, Elaut G, et al: Inhibition of NF-kappaB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes. Cell Prolif 40: 640-655, 2007.
20. Fabre C, Grosjean J, Tailler M, et al: A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 7: 2139-2145, 2008.
21. Halili MA, Andrews MR, Sweet MJ and Fairlie DP: Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 9: 309-319, 2009.
22. Srinivasan B, Johnson TE, Lad R and Xing C: Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3′,4′, 5′-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities. J Med Chem 52: 7228-7235, 2009.
23. Yadav VR, Prasad S, Sung B and Aggarwal BB: The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int Immunopharmacol 11: 295-309, 2011.
24. Edwards ML, Stemerick DM and Sunkara PS: Chalcones: a new class of antimitotic agents. J Med Chem 33: 1948-1954, 1990.
25. Lawrence NJ, McGown AT, Ducki S and Hadfield JA: The interaction of chalcones with tubulin. Anticancer Drug Des 15: 135-141, 2000.
26. Orlikova B, Tasdemir D, Golais F, Dicato M and Diederich M: The aromatic ketone 4′-hydroxychalcone inhibits TNFalpha-induced NF-kappaB activation via proteasome inhibition. Biochem Pharmacol 82: 620-631, 2011.
27. Pedretti A, Villa L and Vistoli G: VEGA - an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming. J Comput Aided Mol Des 18: 167-173, 2004.
28. Pedretti A, Villa, L and Vistoli G: Atom-type description language: a universal language to recognize atom types implemented in the VEGA program. Theor Chem Acc 109: 229-232, 2003.
29. Tetko IV, Gasteiger J, Todeschini R, et al: Virtual computational chemistry laboratory - design and description. J Comput Aided Mol Des 19: 453-463, 2005.
30. Friesner RA, Banks JL, Murphy RB, et al: Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749, 2004.
31. Halgren TA, Murphy RB, Friesner RA, et al: Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47: 1750-1759, 2004.
32. Ortore G, Di Colo F and Martinelli A: Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities. J Chem Inf Model 49: 2774-2785, 2009.
33. Piccagli L, Fabbri E, Borgatti M, et al: Docking of molecules identified in bioactive medicinal plants extracts into the p50 NF-kappaB transcription factor: correlation with inhibition of NF-kappaB/DNA interactions and inhibitory effects on IL-8 gene expression. BMC Struct Biol 8: 38, 2008.
34. Di Gennaro E, Bruzzese F, Caraglia M, Abruzzese A and Budillon A: Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids 26: 435-441, 2004.
35. Shen KH, Chang JK, Hsu YL and Kuo PL: Chalcone arrests cell cycle progression and induces apoptosis through induction of mitochondrial pathway and inhibition of nuclear factor kappa B signalling in human bladder cancer cells. Basic Clin Pharmacol Toxicol 101: 254-261, 2007.
36. Lee ST, Wong PF, Cheah SC and Mustafa MR: Alpha-tomatine induces apoptosis and inhibits nuclear factor-kappa B activation on human prostatic adenocarcinoma PC-3 cells. PLoS One 6: e18915, 2011.
37. Chen L, Fischle W, Verdin E and Greene WC: Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657, 2001.
38. Krämer OH, Baus D, Knauer SK, et al: Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 20: 473-485, 2006.
39. Butler KV, Kalin J, Brochier C, Vistoli G, Langley B and Kozikowski AP: Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132: 10842-10846, 2010.
40. Tang W, Luo T, Greenberg EF, Bradner JE and Schreiber SL: Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett 21: 2601-2605, 2011.
41. Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ and Lee KT: Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur J Pharmacol 584: 175-184, 2008.
42. Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB and Aggarwal BB: Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J Biol Chem 282: 17340-17350, 2007.
43. Orlikova B, Tasdemir D, Golais F, Dicato M and Diederich M: Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr 6: 125-147, 2011.